Verastem (VSTM) Enters Wnt Inhibitor Collaboration w/ Eisai
Tweet Send to a Friend
Up)
Verastem, Inc., (NASDAQ: VSTM) announced a research collaboration with Eisai for the next-generation of small molecule Wnt inhibitors.
Verastem scientific co-founder and chair of the Scientific Advisory Board, Robert Weinberg, Ph.D., published a report in 2011 in the journal Cell describing the critical nature of the Wnt pathway in the development and maintenance of cancer stem cells.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Verastem scientific co-founder and chair of the Scientific Advisory Board, Robert Weinberg, Ph.D., published a report in 2011 in the journal Cell describing the critical nature of the Wnt pathway in the development and maintenance of cancer stem cells.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Rigel Pharma (RIGL) Advances R348 to Phase 2
- Comstock Mining (LODE) Fully Pays Down $5M Secured Facility
- NPS Pharmaceuticals (NPSP) Prices 6M Common Stock Offering
Create E-mail Alert Related Categories
Corporate News, FDA
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
